Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

7.60
+0.14501.95%
Pre-market: 7.50-0.0950-1.25%07:07 EDT
Volume:1.00M
Turnover:7.62M
Market Cap:501.37M
PE:-2.02
High:7.73
Open:7.31
Low:7.20
Close:7.45
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.62
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:6.99
PE(LYR):-2.02

Loading ...

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

MT Newswires Live
·
May 15

Regenxbio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Regenxbio Falls 28.9% After Late-Stage Data for Muscle Disorder Therapy

THOMSON REUTERS
·
May 14

BUZZ-U.S. STOCKS ON THE MOVE-Klarna, Biogen, Legence

Reuters
·
May 14

Regenxbio expects cash, equivalents to fund operations into early 2027

TIPRANKS
·
May 14

Regenxbio’s RGX-202 shows efficacy in Phase 3 Duchenne trial

TIPRANKS
·
May 14

Regenxbio Shares Down 19.6% Premarket After Co Reports Duchenne Drug Late-Stage Trial Data

THOMSON REUTERS
·
May 14

Regenxbio Meets Primary Endpoint in Duchenne Muscular Dystrophy Study

Dow Jones
·
May 14

Regenxbio Q1 FY26 net loss widens to $90.05 million; revenue drops 92.82% to $6.39 million

Reuters
·
May 14

Regenxbio Q1 revenue drops sharply, posts net loss

Reuters
·
May 14

Regenxbio Q1 EPS $(1.72) Misses $(1.39) Estimate, Sales $6.393M Miss $26.322M Estimate

Benzinga Earnings
·
May 14

BRIEF-Regenxbio Q1 Net Income USD -90.051 Million

Reuters
·
May 14

Regenxbio Reports First Quarter 2026 Financial Results and Operational Highlights

THOMSON REUTERS
·
May 14

Regenxbio Q1 License & Royalty Revenue USD 5.09 Million

THOMSON REUTERS
·
May 14

Regenxbio Q1 Operating Expenses USD 89.755 Million

THOMSON REUTERS
·
May 14

Regenxbio Inc - Expects Cash Position to Fund Operations Into Early 2027

THOMSON REUTERS
·
May 14

Regenxbio's muscle disorder therapy meets main goal in late-stage study

Reuters
·
May 14

Regenxbio Inc - Rgx-202 Shows Favorable Safety Profile With >80% Full Capsid Purity

THOMSON REUTERS
·
May 14

Regenxbio Inc - Plans Potential Commercial Launch of Rgx-202 in 2027

THOMSON REUTERS
·
May 14

Regenxbio Inc - Two Serious Adverse Events Reported, Both Resolved Without Sequelae

THOMSON REUTERS
·
May 14